Endocrine side effects during cancer treatment. Lecture for practitioners

Abstract

Targeted therapy and immune checkpoint inhibitors (ICI) are increasingly being used to treat many solid tumors. The use alpelisib and ICPI has a risk of side-effects, particularly endocrine dysfunctions. In this lecture, there are clearly stated: initial screening, monitoring, selection of therapy and emergency situations for each endocrinopathy, i.e. hyperglycemia during treatment with alpelisib and destructive thyroiditis and hypophysitis during treatment of ICI.

Keywords

• hyperglycemia
• destructive thyroiditis
• hypophysitis
• alpelisib
• immune checkpoint inhibitors